Market Access in the Middle East
How Pricing Reform Impacts Pharmaceutical Uptake Strategies
Despite political and social unrest percolating in parts of the region, the Middle East pharmaceutical market is experiencing strong growth. With government policies and investments supporting the growing healthcare infrastructure, multinational companies are seeing keen opportunities to tap into the region’s economic potential. Although the strong growth ensures an attractive market, characteristics such as rigid price controls, low per capita spending on health in some regions, and the GCC price harmonisation process can make navigating the landscape challenging.
Leveraging interviews with industry, physicians, and payors, in-depth secondary research, and regional market access expertise, Market Access in the Middle East: How Pricing Reform Impacts Pharmaceutical Uptake Strategies provides the insights and analysis needed to fully capitalise on this growing market.
Answering your key questions
- What are the opportunities and challenges for launching drugs and ensuring strong uptake in the Middle East?
- What is the current pricing and reimbursement framework and legislation for both branded drugs and biosimilars in these markets and what will future legislation yield?
- What are the main drivers for uptake for both branded and biosimilar products?
- What are the best practice recommendations for market access?
- Saudi Arabia
- GCC (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE)